Vizgen to Present New Capabilities and Data from the MERSCOPE™ Spatial Transcriptomics Platform at Advances in Genome Biology and Technology (AGBT) General Meeting

New data demonstrates sensitivity, specificity, and biological accuracy of MERSCOPE™ spatial transcriptomics platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, will present new data supporting the exceptional sensitivity, biological accuracy, and specificity of the company’s MERSCOPE™ Platform in addition to data describing the great quality performance using highly-multiplexed 500 gene panels for Neurobiology and Oncology applications at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting, occurring February 6-9, 2023.

The data to be presented by George Emanuel, Ph.D., Scientific Co-founder, Sr. Director of Technology & Partnerships at Vizgen, demonstrates the use of the MERSCOPE Platform for multiomic analysis in more than 10 FFPE tissue types from mouse and human samples with RNA and protein co-detection on the same sections. With single-cell resolution, the MERSCOPE Platform accurately recapitulates known biology and identified rare cell types. The MERSCOPE FFPE workflow maintains high accuracy and sensitivity in comparison to the fresh frozen protocol and has superior data quality as compared to other spatial genomics platforms.

“The data we’re presenting at AGBT underscores the capabilities of Vizgen’s MERSCOPE Platform,” said Terry Lo, President and CEO of Vizgen. “As we continue to expand the boundaries of what is possible with spatial genomics, superior data quality, accuracy and sensitivity remain our primary goal.”

In addition to Dr. Emanuel’s presentation, data will be presented demonstrating the performance of MERSCOPE™ high plex panels designed to measure important biology in human health and disease. Renchao Chen, Ph.D., is presenting a poster showcasing single-cell profiling with a 500 plex neurobiology panel, generating data on over two million cells with precise gene expression and spatial information across the mouse brain. This data represents the most comprehensive map of the mouse brain and describes the neuronal diversity underlying the anatomical and functional structures.

Additionally, Leiam Colbert, Ph.D., is presenting a poster featuring the MERSCOPE Platform's ability to characterize tumor heterogeneity and cell diversity across 6 human cancers using a 500-gene pan-cancer MERFISH panel. The data generated detailed 3- dimensional maps with sufficient resolution to detect morphological features specific to different tissue types and identified 3 major canonical drivers of hepatocellular carcinoma demonstrating the ability of MERFISH data generated to unravel complex tumor biology.

AGBT Presentation Details

Date: Tuesday, February 7, 1:30 – 3:30 p.m. ET
Title: In situ single-cell transcriptomic imaging in formalin-fixed paraffin-embedded (FFPE) tissues with MERSCOPE™
Presented By: George Emanuel, Ph.D., Scientific Co-founder, Sr. Director of Technology & Partnerships, Vizgen
Poster Number: 539
Location: Diplomat Resort, Regency Ballroom 1-3

Date: Wednesday, February 8, 4:45 – 6:10 p.m. ET
Title: Analyzing the molecular basis underlying anatomic and functional complexity of the mouse brain with MERSCOPE™
Presented By: Renchao Chen, Ph.D., Applications Scientist, Vizgen
Poster Number: 402
Location: Diplomat Resort, Regency Ballroom 1-3

Date: Wednesday, February 8, 4:45 – 6:10 p.m. ET
Title: Characterizing tumor heterogeneity and cell diversity across multiple cancer types
Presented By: Leiam Colbert, Ph.D., Product Applications Manager, Vizgen
Poster Number: 101
Location: Diplomat Resort, Regency Ballroom 1-3

About Vizgen

Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field. The company’s MERSCOPE™ Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. Powered by the proven MERFISH (Multiplexed error robust in situ hybridization) technology, over 60 publications demonstrate how these tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The MERSCOPE™ Platform provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to www.vizgen.com. Connect on social media Twitter, LinkedIn and Facebook.